BACKGROUND: Infliximab has been shown to have beneficial effects on bone metabolism in patients with Crohn's disease (CD) although as yet the exact mechanisms have not been fully elucidated. AIM: To evaluate the impact of adalimumab therapy on bone metabolism using a combined in vivo and in vitro model. METHODS: Parathyroid hormone, vitamin D, bone formation markers, bone resorption marker, pro-inflammatory cytokines, anti-inflammatory cytokines, osteoprotegerin, and sRANKL were measured in control patients and pre- and post-treatment with adalimumab in CD patients. The effect of control patients' and pre- and post-treatment CD patients' sera on human osteoblasts (hFOB 1.19) in vitro cell viability and differentiation was also analyzed. RESULTS: There was a significant increase in bone formation markers osteocalcin (P < 0.05) and procollagen type 1 N-terminal propeptide (P < 0.01) at 1 and 3 months post-treatment. Moreover, there was a sustained but not significant fall in serum CTx, a bone resorption marker. No significant change was seen over time with other parameters measured. Serum from CD patients pre-treated with adalimumab showed increased osteoblast viability compared with that of post-treated patients at 6 months (P = 0.002) and controls. However, post-adalimumab treatment sera at 6 months appeared to increase osteoblast differentiation (P = 0.001), which is likely to be important in new bone formation. CONCLUSIONS: This first study evaluating the role of adalimumab as a possible bone protector in Crohn's disease patients has shown that similar to infliximab, adalimumab has complex and potentially beneficial effects on bone metabolism.
BACKGROUND:Infliximab has been shown to have beneficial effects on bone metabolism in patients with Crohn's disease (CD) although as yet the exact mechanisms have not been fully elucidated. AIM: To evaluate the impact of adalimumab therapy on bone metabolism using a combined in vivo and in vitro model. METHODS:Parathyroid hormone, vitamin D, bone formation markers, bone resorption marker, pro-inflammatory cytokines, anti-inflammatory cytokines, osteoprotegerin, and sRANKL were measured in control patients and pre- and post-treatment with adalimumab in CDpatients. The effect of control patients' and pre- and post-treatment CDpatients' sera on human osteoblasts (hFOB 1.19) in vitro cell viability and differentiation was also analyzed. RESULTS: There was a significant increase in bone formation markers osteocalcin (P < 0.05) and procollagen type 1 N-terminal propeptide (P < 0.01) at 1 and 3 months post-treatment. Moreover, there was a sustained but not significant fall in serum CTx, a bone resorption marker. No significant change was seen over time with other parameters measured. Serum from CDpatients pre-treated with adalimumab showed increased osteoblast viability compared with that of post-treated patients at 6 months (P = 0.002) and controls. However, post-adalimumab treatment sera at 6 months appeared to increase osteoblast differentiation (P = 0.001), which is likely to be important in new bone formation. CONCLUSIONS: This first study evaluating the role of adalimumab as a possible bone protector in Crohn's diseasepatients has shown that similar to infliximab, adalimumab has complex and potentially beneficial effects on bone metabolism.
Authors: M Komatsu; D Kobayashi; K Saito; D Furuya; A Yagihashi; H Araake; N Tsuji; S Sakamaki; Y Niitsu; N Watanabe Journal: Clin Chem Date: 2001 Impact factor: 8.327
Authors: Charlotte L M Krieckaert; Michael T Nurmohamed; Gertjan Wolbink; Willem F Lems Journal: Rheumatology (Oxford) Date: 2012-12-05 Impact factor: 7.580
Authors: B M Ryan; M G V M Russel; L Schurgers; M Wichers; J Sijbrandij; R W Stockbrugger; E Schoon Journal: Aliment Pharmacol Ther Date: 2004-10-15 Impact factor: 8.171
Authors: Dolores Sgambato; Francesca Gimigliano; Cristiana De Musis; Antimo Moretti; Giuseppe Toro; Emanuele Ferrante; Agnese Miranda; Domenico De Mauro; Lorenzo Romano; Giovanni Iolascon; Marco Romano Journal: World J Clin Cases Date: 2019-08-06 Impact factor: 1.337